PLRX - NASDAQ
Pliant Therapeutics, Inc.
$1.18
-1.7%Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live SnapshotPliant Therapeutics, Inc. Management Team
Mr. Johannes P. Hull J.D.
Chief Business Officer
Compensation
$654,524
Dr. Keith Lamont Cummings M.B.A., M.D.
Chief Financial Officer
Compensation
$713,074
Dr. Eric A. Lefebvre M.D.
Chief Medical Officer
Compensation
$762,338
Ms. Delphine Imbert Ph.D.
Chief Technical Officer
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,078,624
Dr. Rik Derynck Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Christopher S. Keenan
Vice President of Investor Relations & Corporate Communications
Pliant Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $435K and sold $164K worth of PLRX shares, resulting in $271K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
127.8K
163.62K
-164K
-$164K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
270.0K
434.70K
0
0.00
+435K
+$435K
Top Buyers
Pyott David E I
Director
$48K
Huh Hoyoung
Director
$48K
Crowell Gayle A
Director
$48K
Bruhn Suzanne Louise
Director
$48K
Mccourt Thomas A
Director
$48K
Top Sellers
Coulie Bernard
Director, Officer: President And Ceo
$114K
Cummings Keith Lamont
Officer: Chief Financial Officer
$31K
Cheung Lily
Officer: Chief Human Resource Officer
$10K
Kuo Minnie
Officer: Chief Operating Officer
$9K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $271K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Insider Participation
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
PLRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 22, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 26, 2023 | April 26, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 29, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.